Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

retatrutide

  • Home
  • retatrutide
Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes

Posted by MedXY By MedXY 05/16/2026
Post-hoc metabolomic and lipidomic analyses from two phase 2 trials suggest retatrutide favorably remodels metabolic pathways linked to fatty acid oxidation, insulin resistance, and triglyceride composition in obesity, with and without type 2 diabetes.
Read More
Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Posted by MedXY By MedXY 08/02/2025
Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.
Read More
  • High-Dose Vitamin C After Cardiac Arrest: Promise Meets a Negative Signal in VITaCCA
  • When Does an ICP Crisis Really Count? BOOST II Raises Questions About Bedside Detection in Severe TBI
  • When Shift Hours Add Up: Emergency Department Medication Errors Rise as Clinicians Get Tired
  • Why an EHR-Embedded OUD Intervention Still Struggled: Lessons from 12 Colorado Hospitals
  • Updated COVID-19 Vaccination and Cardiovascular Protection: What a Large VA Study Found in 2024-2025
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in